ArticleCureus2025
Ductal Carcinoma In Situ of the Breast: An Analysis of 12 Years of Experience From a Tertiary Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Ductal carcinoma in situ (DCIS) is a non-invasive breast malignancy that accounts for approximately one-fifth of new breast cancer diagnoses in developed countries. While not life-threatening, DCIS is a potential precursor to invasive carcinoma, and optimal management remains a matter of debate. Adjuvant radiotherapy after breast-conserving surgery reduces the risk of local recurrence, and hypofractionated regimens have emerged as an effective and convenient alternative to conventional fractionation. This study aimed to compare acute and late toxicity profiles between hypofractionated and conventional radiotherapy in DCIS patients, with a particular focus on the impact of boost administration. Methodology This retrospective study included 97 female patients with histologically confirmed DCIS treated between January 2013 and January 2025. Patients with invasive components, prior malignancy, or incomplete data were excluded. Radiotherapy was delivered using three-dimensional conformal radiotherapy (n = 43) or intensity-modulated radiotherapy (n = 54), with conventional fractionation (50 Gy/25 fractions, used in 30.9% (30 patients)) or hypofractionated regimens (40-42.6 Gy/15-16 fractions, used in 69.1% (67 patients)). A sequential boost of 10 Gy was applied in high-risk cases. Data were analyzed using SPSS version 27.0 (IBM Corp., Armonk, NY, USA), with significance set at p-values <0.05. Results A total of 97 DCIS patients received adjuvant radiotherapy (mean age: 51 years). Hypofractionated radiotherapy was used in 69.1% (67 patients), and conventional fractionation in 30.9% (30 patients). Acute toxicity occurred in 60.8% (59 patients), while late toxicity was rare (8.2% (8 patients)) and similar across groups. Boost administration was associated with increased acute toxicity in the hypofractionated group (p = 0.044) but not in the conventional group. Only one local recurrence was observed during follow-up. Conclusions Our findings confirm that both hypofractionated and conventional radiotherapy provide excellent local control and acceptable toxicity in DCIS patients, with boost administration significantly increasing acute toxicity in hypofractionated regimens. Despite these differences, long-term outcomes remain favorable, supporting the role of individualized risk-adapted radiotherapy strategies in DCIS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.